Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 26Non-Muscle Invasive Bladder Neoplasms 11Colorectal Neoplasms 3Colonic Neoplasms 3Recurrence 2Neoplasms 2Melanoma 2Lung Neoplasms 2Side Effect of Drug 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Osteosarcoma 1Oligospermia 1Neuroblastoma 1Fibrosis 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma in Situ 1Breast Neoplasms 1

Interventions

pembrolizumab 92Gemcitabine 55Nivolumab 49Cisplatin 38atezolizumab 31Carboplatin 30avelumab 25enfortumab vedotin 24Docetaxel 23Magnetic Resonance Spectroscopy 18Ipilimumab 17Paclitaxel 16Mitomycin 15Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Transitional Cell × BCG Vaccine × Clear all
NCT00070070 2022-10-12

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Ludwig Institute for Cancer Research

Phase 1 Completed
6 enrolled 7 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡